Risk factors for brain metastases in patients with non-small-cell lung cancer

被引：34

作者：

An, Ning ^{[1
]}

Jing, Wang ^{[2
]}

Wang, Haoyi ^{[3
]}

Li, Ji ^{[2
]}

Liu, Yang ^{[2
]}

Yu, Jinming ^{[2
]}

Zhu, Hui ^{[2
]}

机构：

[1] Shandong Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China

[2] Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China

[3] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Shandong, Peoples R China

来源：

CANCER MEDICINE | 2018年 / 7卷 / 12期

关键词：

brain metastases; gene mutation; non-small-cell lung cancer; prophylactic cranial irradiation; PROPHYLACTIC CRANIAL IRRADIATION; GROWTH-FACTOR-RECEPTOR; CARCINOEMBRYONIC ANTIGEN LEVEL; NEURON-SPECIFIC ENOLASE; EGFR MUTATION STATUS; MULTIMODALITY TREATMENT; CEREBRAL METASTASES; CLINICAL-RESPONSE; KRAS MUTATION; PRIMARY TUMOR;

D O I：

10.1002/cam4.1865

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Brain metastases (BM) are severe incidents in patients with non-small-cell lung cancer (NSCLC). The controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival benefit prompted us to explore the possible risk factors for BM in NSCLC and identify the potential population most likely to benefit from PCI. Risk factors for brain metastases in NSCLC are reviewed in this article. Identifying patients with a higher risk of BM could possibly increase the benefit of PCI while reducing the discomfort and risks caused by unnecessary invasive procedures in the NSCLC patient population. Future studies might focus on finding a solid basis for the prediction of the occurrence of brain metastases and for the therapeutic decision on the use of PCI.

引用

页码：6357 / 6364

页数：8

共 95 条

[1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].

ALBAIN, KS ;

RUSCH, VW ;

CROWLEY, JJ ;

RICE, TW ;

TURRISI, AT ;

WEICK, JK ;

LONCHYNA, VA ;

PRESANT, CA ;

MCKENNA, RJ ;

GANDARA, DR ;

FOSMIRE, H ;

TAYLOR, SA ;

STELZER, KJ ;

BEASLEY, KR ;

LIVINGSTON, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892

[2]

[Anonymous], DIAGN TREATM LUNG CA

[3] Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis [J].

Arrieta, Oscar ;

Saavedra-Perez, David ;

Kuri, Roberto ;

Aviles-Salas, Alejandro ;

Martinez, Luis ;

Mendoza-Posada, Daniel ;

Castillo, Patricia ;

Astorga, Alma ;

Guzman, Enrique ;

De la Garza, Jaime .

BMC CANCER, 2009, 9

[4] Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer [J].

Baik, Christina S. ;

Chamberlain, Marc C. ;

Chow, Laura Q. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) :1268-1278

[5] Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma [J].

Bajard, A ;

Westeel, V ;

Dubiez, A ;

Jacoulet, P ;

Pernet, D ;

Dalphin, JC ;

Depierre, A .

LUNG CANCER, 2004, 45 (03) :317-323

[6] Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer [J].

Barak, Vivian ;

Holdenrieder, Stefan ;

Nisman, Benjamin ;

Stieber, Petra .

CANCER BIOMARKERS, 2010, 6 (3-4) :191-196

[7] Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis [J].

Benedettini, Elisa ;

Sholl, Lynette M. ;

Peyton, Michael ;

Reilly, John ;

Ware, Christopher ;

Davis, Lenora ;

Vena, Natalie ;

Bailey, Dyane ;

Yeap, Beow Y. ;

Fiorentino, Michelangelo ;

Ligon, Azra H. ;

Pan, Bo-Sheng ;

Richon, Victoria ;

Minna, John D. ;

Gazdar, Adi F. ;

Draetta, Giulio ;

Bosari, Silvano ;

Chirieac, Lucian R. ;

Lutterbach, Bart ;

Loda, Massimo .

AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (01) :415-423

[8] ROLE OF PDL1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES (TILS) IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM) [J].

Berghoff, A. S. ;

Woehrer, A. W. ;

Widhalm, G. ;

Oberndorfer, F. ;

Dieckmann, K. ;

Filipits, M. ;

Marosi, C. ;

Hoeller, C. ;

Wick, W. ;

Preusser, M. .

ANNALS OF ONCOLOGY, 2014, 25

[9]

Bhatt VR, 2017, J GLOB ONCOL, V3, P208, DOI 10.1200/JGO.2016.003392

[10] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].

Brugger, Wolfram ;

Triller, Nadja ;

Blasinska-Morawiec, Maria ;

Curescu, Stefan ;

Sakalauskas, Raimundas ;

Manikhas, Georgy Moiseevich ;

Mazieres, Julien ;

Whittom, Renaud ;

Ward, Carol ;

Mayne, Karen ;

Trunzer, Kerstin ;

Cappuzzo, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120

← 1 2 3 4 5 6 7 8 9 10 →